Sunovion. Latuda (Lurasidone HCl) Tablets: Highlights of Prescribing Information.
Sunovion, 2013 (http://www.latuda.com/LatudaPrescribingInformation.pdf).
European Medicines Agency. Latuda: EPAR – Product Information. Annex I: Summary of Product Characteristics.
EMA, 2014 (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf).
Citrome, L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract
2011; 65: 189–210.
Citrome, L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther
2012; 29: 815–25.
Citrome, L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Clin Schizophr Relat Psychoses
2012; 6: 76–85.
Citrome, L, Ketter, TA, Cucchiaro, J, Loebel, A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord
2014; 155: 20–7.
Ishibashi, T, Horisawa, T, Tokuda, K, Ishiyama, T, Ogasa, M, Tagashira, R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther
2010; 334: 171–81.
Horiguchi, M, Huang, M, Meltzer, HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol and Exp Ther
2011; 338: 605–14.
Cates, LN, Roberts, AJ, Huitron-Resendiz, S, Hedlund, PB. Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology
2013; 70: 211–7.
Blier, P, Ward, NM. Is there a role for 5-HT1A agonists in the treatment of depression?
2003; 53: 193–203.
Ohno, Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther
2011; 17: 58–65.
Preskorn, S, Ereshefsky, L, Chiu, YY, Poola, N, Loebel, A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol
2013; 28: 495–505.
Chiu, YY, Ereshefsky, L, Preskorn, SH, Poola, N, Loebel, A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact
Ogasa, M, Kimura, T, Nakamura, M, Guarino, J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl)
2013; 225: 519–30.
Nakamura, M, Ogasa, M, Guarino, J, Phillips, D, Severs, J, Cucchiaro, J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry
2009; 70: 829–36.
Nasrallah, HA, Silva, R, Phillips, D, Cucchiaro, J, Hsu, J, Xu, J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res
2013; 47: 670–7.
Meltzer, HY, Cucchiaro, J, Silva, R, Ogasa, M, Phillips, D, Xu, J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry
2011; 168: 957–67.
Loebel, A, Cucchiaro, J, Sarma, K, Xu, L, Hsu, C, Kalali, AH, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res
2013; 145: 101–9.
Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep
1962; 10: 799–812.
Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
McEvoy, JP, Citrome, L, Hernandez, D, Cucchiaro, J, Hsu, J, Pikalov, A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry
2013; 74: 170–9.
Citrome, L, Cucchiaro, J, Sarma, K, Phillips, D, Silva, R, Tsuchiya, S, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol
2012; 27: 165–76.
Loebel, A, Cucchiaro, J, Xu, J, Sarma, K, Pikalov, A, Kane, JM. Effectiveness of lurasidone v. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res
2013; 147: 95–102.
Harvey, PD, Siu, CO, Hsu, J, Cucchiaro, J, Maruff, P, Loebel, A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol
2013; 23: 1373–82.
Citrome, L, Weiden, PJ, McEvoy, JP, Correll, CU, Cucchiaro, J, Hsu, J, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr
Stahl, SM, Cucchiaro, J, Simonelli, D, Hsu, J, Pikalov, A, Loebel, A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry
2013; 74: 507–15.
Tandon, R, Loebel, A, Phillips, D, Pikalov, A, Hernandez, O, Mao, Y, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia [abstract]. Schizophr Res
2014; 153 (suppl 1): S372.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Latuda (International Non-Proprietary Name: Lurasidone).
Judd, LL, Akiskal, HS, Schettler, PJ, Endicott, J, Maser, J, Solomon, DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry
2002; 59: 530–7.
Ketter, TA, Citrome, L, Wang, PW, Culver, JL, Srivastava, S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
Acta Psychiatr Scand
2011; 123: 175–89.
Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Hsu, J, Sarma, K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry
2014; 171: 160–8.
Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Sarma, K, Xu, J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry
2014; 171: 169–77.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Belmaker, RH. Lurasidone and bipolar disorder. Am J Psychiatry
2014; 171: 131–3.